StemCell Therapy

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Given this risk, we thought wed take a look at whether Vir Biotechnology (NASDAQ:VIR) shareholders should be worried about its cash burn. In this report, we will consider the companys annual negative free cash flow, henceforth referring to it as the cash burn. Well start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Vir Biotechnology

A companys cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2019, Vir Biotechnology had cash of US$320m and no debt. Importantly, its cash burn was US$130m over the trailing twelve months. That means it had a cash runway of about 2.5 years as of September 2019. Thats decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below.

Some investors might find it troubling that Vir Biotechnology is actually increasing its cash burn, which is up 39% in the last year. And we must say we find it concerning that operating revenue dropped 4.0% over the same period. Taken together, we think these growth metrics are a little worrying. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Even though it seems like Vir Biotechnology is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash to fund growth. By comparing a companys annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$1.6b, Vir Biotechnologys US$130m in cash burn equates to about 8.2% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another years growth by issuing some new shares to investors, or even by taking out a loan.

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Vir Biotechnologys cash runway was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, were not too worried about its rate of cash burn. While we always like to monitor cash burn for early stage companies, qualitative factors such as the CEO pay can also shed light on the situation. Click here to see free what the Vir Biotechnology CEO is paid..

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more:
Companies Like Vir Biotechnology (NASDAQ:VIR) Are In A Position To Invest In Growth - Simply Wall St

Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences, announced today the promotion of Michael Krel, PhD, to Partner of the Industrial Biotechnology team. Mr. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.

"This promotion recognizes Michaels excellent skills in the field of industrial biotech, and also reinforces the leading role that Sofinnova Partners is playing in this emerging sector," said Denis Lucquin, Managing Partner of Sofinnova Partners. "We look forward to working with Michael in his new role, and to the continued value his experience and deep subject area expertise bring to our pioneering work in this space."

Mr. Krel said, "It has been a privilege to serve the firm, and to help pioneer its development in Industrial Biotech. I look forward to continuing our work in this important area, and to the potential impact these investments will have globally."

Sofinnova Partners Industrial Biotech franchise is dedicated to start-ups with a specific emphasis on synthetic biology, food, feed, agriculture, materials and chemicals, and represents more than 200 M under management.

Mr. Krel joined Sofinnova Partners as a Senior Associate in 2013 and has been involved in the venture capital firms investment activities in industrial biotech since then. Mr. Krel is an observer on the board of Comet Bio and a board member of EnobraQ and Afyren.

Prior to joining Sofinnova Partners, Michael spent six years in industrial biotech start-ups, holding business development positions. Additionally, Michael was a consultant focused on R&D strategic and organizational issues.

Mr. Krel has a graduate degree in engineering from Ecole Polytechnique and holds a PhD in organic chemistry from Paris X Orsay University.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management.

For more information, please visit: http://www.sofinnovapartners.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005847/en/

Contacts

Press: Media: Kate BarretteRooneyPartners LLC+1 212 223 0561kbarrette@rooneyco.com

France Anne ReinS&I+33 6 03 35 92 05anne.rein@strategiesimage.com

Read this article:
Sofinnova Partners Announces the Promotion of Michael Krel to Partner of Industrial Biotechnology Team - Yahoo Finance

MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that their subsidiary, Olaregen Therapeutix, Inc., is introducing an exciting new product, Excellagen Aesthetics for the cosmetic surgery and aesthetic dermatology market. FDA 510(k) cleared with an indication for the management of wounds, Excellagen Aesthetics is intended for use following facial rejuvenation procedures, including post-laser surgery, post-chemical peels, and post- skin ablation. Excellagen is a ready to use 3-dimensional wound conforming matrix that supports a favorable wound healing environment. It is designed to activate collagen, accelerate granulation, and promote new tissue growth by providing a structural scaffold for cellular migration and proliferation. Excellagen Aesthetics has been shown in vitro to trigger the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biological mediator of wound healing.

Olaregen is rolling out Excellagen Aesthetics with a dedicated contract sales force uniquely positioned in major metropolitan areas across the United States where the majority of aesthetic dermatology procedures are clustered. Americans spent an estimated $8 billion on surgical and non-surgical aesthetic dermatology procedures in 2018 when there were over 340,000 facial rejuvenation performed.

Scott Emmens, Senior Vice President of Sales and Business Development at Olaregen commented, We have been working closely with the aesthetic dermatology community, and Excellagen Aesthetics is being tested with some leading dermatologists who are conducting case studies to evaluate the efficacy of our cellular tissue product in wound management as measured by patient reported down-time as well as patient satisfaction with post-treatment care. We are enthusiastic about the early response from patients and doctors who have tried the product after facial rejuvenation procedures including micro-needling and laser skin resurfacing, two procedures that result in post-treatment pain and significant healing times that limit daily activities. We look forward to engaging with the dermatology community to introduce Excellagen Aesthetics and show how our FDA-cleared product can be used to the benefit of their patients and their practice.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.

About Olaregen Therapeutix

Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. in bone and joint regeneration comprise the current pipeline. The company's mission is to become a significant force in regenerative medicine and advance the science of healing.

Story continues

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Original post:
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Introduction of Excellagen Aesthetics - Yahoo Finance

Menlo Therapeutics Inc (MNLO) is near the top in its industry group according to InvestorsObserver. MNLO gets an overall rating of 58. That means it scores higher than 58 percent of stocks. Menlo Therapeutics Inc gets a 72 rank in the Biotechnology industry. Biotechnology is number 60 out of 148 industries.

Click Here to get the full Stock Score Report on Menlo Therapeutics Inc (MNLO) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Menlo Therapeutics Inc (MNLO) stock is trading at $6.10 as of 12:18 PM on Tuesday, Jan 14, a rise of $0.50, or 8.93% from the previous closing price of $5.60. The stock has traded between $5.50 and $6.44 so far today. Volume today is light. So far 132,809 shares have traded compared to average volume of 181,677 shares.

To see InvestorsObserver's Sentiment Score for Menlo Therapeutics Inc click here.

Excerpt from:
Is Menlo Therapeutics Inc (MNLO) Stock a Good Buy in Biotechnology - InvestorsObserver

Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.

At J.P. Morgan conference, the British company announced that Astellas has agreed to co-develop and co-commercialize stem-cell derived allogeneic CAR-T and TCR T-cell therapies against up to three targets. In contrast to current autologous T cell therapies, allogenic T cell therapies might be manufactured in a central facility reducing production cost significantly compared to autologous cell production and logistics.

Under the agreement, Adaptimmune will identify and validate new targets for generating target-specific T-cell receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently from the HLA profile of the tumour cell. Astellas subsidiary Universal Cells, Inc will provide its Universal Donor Cell and Gene Editing Platform, which makes use of a stem cell-tropic rAAV vector for engineering humanpluripotent stem cells to contain deletions, insertions, or point mutations at any genomic position.

Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited induced pluripotent stem cell (iPSC) lines that generate proprietary T-cell products without the use of feeder layers.

Under the agreement, Astellas will fund research up until completion of a Phase I trial for each candidate with US$7.5m per year. Subsequently, Astellas and Adaptimmune may opt for co-development and co-commercialization of the candidate, or independent development through a milestone and royalty bearing licence. Under the agreement, Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates on its own.

In case of Astellas would develop the candidates on its own, Adaptimmune may receive up to$897.5m in payments. If Adaptimmune would do so, Astellas may receive up to US$552.5m. If the companies opt for co-commercialisation any T-cell therapy, costs and profits will be shared equally.

Read the original:
Astellas and Adaptimmune team up in CAR-T development - European Biotechnology

Global Chromatography in Biotechnology market 2020 in depth research by industry competitive landscape, size, growth rate, strategy, trends and forecast 2026.

The global Chromatography in Biotechnology market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, titled global Chromatography in Biotechnology market, offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Chromatography in Biotechnology market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. A team subject-matter experts have provided the readers a qualitative and quantitative data about the market and the various elements associated with it.

Get the Sample of this Report@https://www.qyresearch.com/sample-form/form/1456217/global-chromatography-in-biotechnology-market

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Chromatography in Biotechnology market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Market Segments Covered:

The following players are covered in this report:Bio-Rad Laboratories Inc.Danaher Corp.MilliporeSigmaQiagenScion InstrumentsThermo Fisher Scientific Inc.PerkinelmerGe Healthcare Life SciencesAntec ScientificAsynt Ltd.Chromatography in Biotechnology Breakdown Data by TypeGas ChromatographyThin Layer ChromatographySupercritical Fluid ChromatographyLiquid ChromatographyHPLC/UHPLCAffinity ChromatographyChromatography in Biotechnology Breakdown Data by ApplicationCancer Research CentersCancer HospitalPharmaceuticalPathological SectorsCompanies and Academic InstitutionsOthers

Regions Covered in the Global Chromatography in Biotechnology Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report Accurate market size and CAGR forecasts for the period 2019-2025 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Chromatography in Biotechnology market Exhaustive research on innovation and other trends of the global Chromatography in Biotechnology market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report segments the global Chromatography in Biotechnology market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Chromatography in Biotechnology market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1456217/global-chromatography-in-biotechnology-market

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Chromatography in Biotechnology market

Chapter 2: Evaluating the leading manufacturers of the global Chromatography in Biotechnology market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Chromatography in Biotechnology market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9 : To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Chromatography in Biotechnology Market Growth 2020-2026 with Competitive Landscape and Top Regions - Weekly Wall

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global biotechnology reagents market since 2014 and the market is poised to grow by USD 37.98 billion during the period 2019-2023, progressing at a CAGR of almost 9% during the forecast period. Request free sample pages

Read the 136-page report with TOC on Biotechnology Reagents Market Analysis Report by Technology (Chromatography, In-vitro diagnostics, Polymerase chain reaction, Cell culture, and Others), Geography (Americas, APAC, and EMEA), and the Segment Forecasts, 2019-2023.

https://www.technavio.com/report/global-biotechnology-reagents-market-industry-analysis

The market is driven by the high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, increasing stem cell and biomedical research is anticipated to boost the growth of the biotechnology reagents market.

The market is observing a significant rise in the demand for biotechnology reagents in diagnostic and therapeutic applications. This is due to advances in technologies such as cell structure, recombinant DNA and biotherapeutics, and emerging neurosciences and proteomics disciplines. The demand for ready-to-use reagents is also growing significantly in clinical laboratories and hospitals as they ensure minimal calculation, dilution, and pipetting errors. They also help reduce the duration of the diagnostic procedure and prevent sample contamination. These factors are crucial in driving the growth of the global biotechnology reagents market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Biotechnology Reagents Market Companies:

Agilent Technologies

Agilent Technologies operates the business through segments such as Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company offers a wide range of biotechnology reagents. Some of the key offerings of the company include Erythrocyte-Lysing Reagent without Fixative, EasyLyse, Erythrocyte-Lysing Reagent, Uti-Lyse, and miRNA qPCR Detection Reagents.

BD

BD operates the business through segments such as BD Medical, BD Life Sciences, and BD Interventional. The company offers a wide range of biotechnology reagents. BD OptiBuild, CD20 PE Clone L27 (ASR), and CD2 APC Clone L303.1 (also known as L303) (ASR) are some of its key offerings.

Bio-Rad Laboratories

Bio-Rad Laboratories operates the business through segments such as life science, clinical diagnostics, and others. iScript RT-qPCR Sample Preparation Reagent, Kovacs Reagent, Anti-D Reference Reagent are some of its key offerings.

GENERAL ELECTRIC

GENERAL ELECTRIC operates the business across various segments such as power, renewable energy, oil & gas, aviation, healthcare, transportation, lighting, and capital. The company offers a wide range of biotechnology reagents. Some of the key offerings of the company include Amersham ECL Detection Reagents, CDP-Star Detection Reagents, and PDEA Thiol Coupling Reagent.

Merck KGaA

Merck KGaA operates the business across segments such as healthcare, life science, and performance materials. The company offers a wide range of biotechnology reagents. Solvents for Liquid Chromatography LiChrosolv, Reagents for Acylation, and Silylation Derivatization Reagent are some of the key offerings of the company.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Technavio has segmented the biotechnology reagents market based on the technology and region.

Biotechnology Reagents Technology Outlook (Revenue, USD Billion, 2019 - 2023)

Biotechnology Reagents Regional Outlook (Revenue, USD Billion, 2019 - 2023)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare include:

Global Affinity Chromatography Reagents Market Global affinity chromatography reagents market by end-users (pharmaceutical and biotechnology industry, food and beverage industry, cosmetic industry, and others) and geography (Asia, Europe, North America, and ROW).

Global Molecular Biology Enzymes, Kits, and Reagents Market Global molecular biology enzymes, kits, and reagents market by end-users (biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and academic institutes and research organizations) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com

Read more from the original source:
Global Biotechnology Reagents Market 2019-2023 | Evolving Opportunities with Agilent Technologies and BD | Technavio - Business Wire

A biotechnology park and incubation centre will be set up in Rajasthan for which a Memorandum of Understanding (MoU) will be signed between the Centre and the state government, Union Secretary, Department of Biotechnology, Renu Swaroop said on Friday.

The park and incubation centre will provide an opportunity to conduct research in the field of biotechnology and employment to the youth, she said.

Swaroop was addressing the State Biotech Cohort Meeting, which was attended by vice chancellors, directors and deans of all universities having biotechnology courses, representatives from institutes conducting research in biotechnology and start-ups associated with it.

Swaroop said the Centre will provide full support and assistance to promote biotechnology in Rajasthan.

The biotechnology park and incubation centre will be set up with the support of Biotechnology Industry Research Assistance Council (BIRAC).

She said utility of biotechnology is increasing in every field, including health, agriculture and agriculture production, industry, edible food, among others. There is a need to promote biotechnology, and encouraging it will give pace to industrial development and research, she added.

Rajasthan Department of Science and Technology Secretary Mugdha Sinha said bio-informatics, biomedical engineering and nano medicine will be encouraged in the state.

The Rajasthan government recently launched Nirogi Rajasthan (Healthy Rajasthan) campaign and all possible assistance through bio-informatics will be provided to strengthen it, she added.

Biotechnology ecosystem and start-ups will be improved in the state with the help from Centre, she said. PTI AG

Like this content? Sign up for our daily newsletter to get latest updates.

See the article here:
BIRAC Supported Biotechnology Park And Incubation Centre In Rajasthan Soon - IndianWeb2.com

A LEADING scientist, writer and broadcaster will tell a conference in Glasgow that start-ups in industrial biotechnology (IB) have to get out and tell people what they are doing.

Writer and broadcaster Vivienne Parry will tell the annual conference of the Industrial Biotechnology Innovation Centre (IBioIC) that scientists can sometimes struggle to present the significance of the work they undertake to help save the planet.

She is one of the keynote speakers at next months conference, which will see more than 450 delegates and a host of companies exhibiting their smart solutions to a global audience.

READ MORE:Scottish Government's broadband pledge exceeds superfast

Parry, a scientist by training, is head of engagement at Genomics England and a member of the UK Research and Innovation Board. She previously had a role on the BBCs Tomorrows World programme.

Writer and broadcaster Vivienne Parry.

She said: Industrial biotechnology start-ups need to get out and tell people what they are doing, quickly demonstrating the solution to a problem.

Scientists can sometimes struggle to communicate to policy makers and the public the significance of what they are doing to save the planet.

Keep it simple and show the real value in your product and the positive impact it can make to everyday life and the environment. When I listen to someone presenting their concepts, I want them to excite me about the potential of their product in a way that is not hyped, but is really clear.

Biotechnology is the science of using plant-based and waste resources to produce or process materials, chemicals and energy, and offers green and sustainable alternatives to fossil fuels in everything from energy to medicines and food packaging.

To date, IBioIC has overseen the doubling of IB in Scotland to more than 350 million and supported more than 130 companies, 50 research projects and 18 Scottish universities and research institutes.

The IBioIC conference will see global experts share their knowledge, challenges, opportunities and best practice, and will again highlight Scotlands capabilities in driving the bio-based economy.

The recent BioCity UK Life Science Start-Up Report revealed Scotland is the leading UK centre for environmental and agricultural biotech start-ups, with positively disproportionate growth to the rest of the UK which is great, said Mark Bustard, commercial director at IBioIC.

READ MORE:Michael Fry's predictions for the advances of the coming decade

But to truly succeed, a change in mindset from great science to

successful manufacturing is needed if they are to capitalise on their innovations. The move to manufacturing generally happens with significant capital investment which they secure from being able to demonstrate robust processes clearly to prospective backers.

Scotland has a national plan for IB and, as a nation, it is rich in natural resources. We just need to capitalise on it in a similar way the Nordic countries have.

Bustard went on to list some of Scotlands success stories in biotech.

There is a growing appreciation and support for the role bio-based industries have in tackling the climate change emergency and creating a circular economy to meet the Governments net zero carbon targets by 2045.

Companies like ScotBio, CelluComp and Celtic Renewables are all fantastic examples of award-winning organisations who are doing just that by driving science to generate and make products. They are creating workforces of innovators who are interested in manufacturing.

Scotland has an eco-system that supports and develops IB talent and IBioICs scale-up facilities provide a platform for academics and entrepreneurs to accelerate growth and demonstrate proof of concept.

View post:
Biotechnologists urged to explain their work's significance - The National

Wall Street analysts expect Unity Biotechnology Inc (NASDAQ:UBX) to report ($0.54) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Unity Biotechnologys earnings. Unity Biotechnology reported earnings of ($0.48) per share in the same quarter last year, which indicates a negative year over year growth rate of 12.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, March 4th.

On average, analysts expect that Unity Biotechnology will report full-year earnings of ($1.99) per share for the current financial year, with EPS estimates ranging from ($2.05) to ($1.93). For the next financial year, analysts expect that the business will post earnings of ($2.17) per share, with EPS estimates ranging from ($2.41) to ($1.93). Zacks Investment Researchs EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Unity Biotechnology.

Unity Biotechnology (NASDAQ:UBX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.49) by ($0.05).

UBX has been the subject of a number of research analyst reports. Mizuho restated a buy rating and set a $33.00 price objective on shares of Unity Biotechnology in a report on Monday, November 18th. ValuEngine upgraded shares of Unity Biotechnology from a buy rating to a strong-buy rating in a report on Friday. Cantor Fitzgerald restated an overweight rating and set a $20.00 price objective on shares of Unity Biotechnology in a report on Thursday, December 12th. Finally, Zacks Investment Research downgraded shares of Unity Biotechnology from a buy rating to a hold rating in a report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Unity Biotechnology presently has an average rating of Buy and a consensus price target of $18.81.

Shares of UBX stock opened at $7.10 on Thursday. The firm has a 50-day moving average of $7.38 and a 200-day moving average of $7.21. Unity Biotechnology has a one year low of $5.61 and a one year high of $16.87.

A number of large investors have recently modified their holdings of the business. Bank of Montreal Can boosted its position in Unity Biotechnology by 164,400.0% during the second quarter. Bank of Montreal Can now owns 4,935 shares of the companys stock worth $47,000 after purchasing an additional 4,932 shares during the period. Aperio Group LLC bought a new position in Unity Biotechnology during the second quarter worth about $50,000. Northern Trust Corp boosted its position in Unity Biotechnology by 2.4% during the second quarter. Northern Trust Corp now owns 242,690 shares of the companys stock worth $2,306,000 after purchasing an additional 5,756 shares during the period. Bank of New York Mellon Corp boosted its position in Unity Biotechnology by 9.6% during the second quarter. Bank of New York Mellon Corp now owns 69,516 shares of the companys stock worth $660,000 after purchasing an additional 6,112 shares during the period. Finally, Tower Research Capital LLC TRC bought a new position in Unity Biotechnology during the third quarter worth about $45,000. Hedge funds and other institutional investors own 35.56% of the companys stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Recommended Story: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

View post:
Analysts Anticipate Unity Biotechnology Inc (NASDAQ:UBX) Will Announce Earnings of -$0.54 Per Share - Riverton Roll

4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat.

Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC inhibitor) and Mercks/Pfizers PD-L1 checkpoint inhibitor avelumab in patients with Merkel cell carcinoma (MCC).

MCC is an orphan, highly immunogenic type of non-melanoma skin cancer. In 2017, avelumab got FDA and EU approval for metastatic MCC. However, about 50% of this patient population do not respond, progress or relapse when treated with avelumab monotherapy. Domatinostatis an orally administered small molecule class I selective HDAC inhibitor which preclinically boosted the anti-tumour immune response, positively affected the tumour microenvironment by facilitating the infiltration of immune cells into the tumour.

In Phase I trials, domatinostat was well tolerated from patietns with several types of advanced hematologic cancers and 4SC observed positive signs of anti-tumour efficacy. To elucidate the potential of domatinostat as a booster of the immune response to tumours, 4SC not only conducts Phase ib/II combination studies with avelumab in MCC but also with MSDs PD1 blocker pembrolizumab in patients with advanced-stage melanoma and with BMS nivolumab.

4SC also conducts a second Phase II study of domatinostat in combination with the avelumab in patients with advanced-stage microsatellite-stable gastrointestinal cancer at The Royal Marsden NHS Foundation Trust in London.

Read the rest here:
Merck and 4SC collaborate in immunooncology - European Biotechnology

Agricultural Biotechnology Market explores effective study on varied sections of Industry like opportunities, size, growth, technology, demand and trend of high leading players. It also provides market key statistics on the status of manufacturers, a valuable source of guidance, direction for companies and individuals interested in the industry. This marketresearchreport looks into and analyzes the Global Agricultural Biotechnology Market and illustrates a comprehensive evaluation of its evolution and its specifications. Another aspect that was considered is the cost analysis of the main products dominant in the Global Market considering the profit margin of the manufacturers.

Biotechnology is a type of scientific technique used in various fields to make improvements & add modified technological advancement. Agricultural biotechnology will include the techniques used to enhance crop productivity & efficiency. It helps farmers to make crop production at cheaper & reasonable rate by using advanced innovative technology. Agricultural biotechnology can be utilized to protect crops from destructive diseases. It is mainly used to modify the genetic sequence of crops and also known as transgenic or genetically modified crops.

Get Free PDF Sample Pages Of Agricultural Biotechnology Market Report: https://www.advancemarketanalytics.com/sample-report/3758-global-agricultural-biotechnology-market

Major Key Players in This Report Include,

Adama Agricultural Solutions Ltd. (China), BASF SE (Germany), Bayer AG (Germany), Certis USA LLC (United States), Dowdupont Inc. (United States), Evogene Ltd. (Israel), Global Bio-Chem Technology Group Company Limited (Hong Kong) and KWS SAAT SE (Germany)

This research is categorized differently considering the various aspects of this market. It also evaluates the current situation and the future of the market by using the forecast horizon. The forecast is analyzed based on the volume and revenue of this market. The tools used for analyzing the Global Agricultural Biotechnology Market research report include SWOT analysis.

The regional analysis of Global Agricultural Biotechnology Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world. Whereas, owing to rising no. of research activities in countries such as China, India, and Japan, Asia Pacific region is also expected to exhibit higher growth rate the forecast period 2019-2025.

For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/3758-global-agricultural-biotechnology-market

The Global Agricultural Biotechnology Market in terms of investment potential in various segments of the market and illustrate the feasibility of explaining the feasibility of a new project to be successful in the near future. The core segmentation of the global market is based on product types, SMEs and large corporations. The report also collects data for each major player in the market based on current company profiles, gross margins, sales prices, sales revenue, sales volume, photos, product specifications and up-to-date contact information.

Table of Content

Global Agricultural Biotechnology Market Research Report

Chapter 1 Global Agricultural Biotechnology Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Productions, Revenue (Value) by Region

Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions

Chapter 6 Global Productions, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Agricultural Biotechnology Market Forecast

Get More Information & Customization: https://www.advancemarketanalytics.com/enquiry-before-buy/3758-global-agricultural-biotechnology-market

Contact Us:

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

The rest is here:
Agricultural Biotechnology Market Boosting the Growth Worldwide: Market Dynamics And Trends, Efficiencies Forecast 2024 - ReportsPioneer

In his greenhouse at the Cold SpringHarbor Laboratory in Long Island, N.Y., plant geneticist Zach Lippman is growing cherry tomatoes.

But they don't look like the ones that most people grow in their gardens and greenhouses.

Lippman's tomatoes have shorter stemsand the fruit is more tightly clustered, looking more like grapes.

"With gene editing, we now have the ability to fine-tune at will," he said. "So instead of having black or white, small fruit [or] big fruit, you can have everything in between."

Lippman used CRISPR arevolutionarygene-editing tool that can quickly and precisely edit DNA to tweak three of the plant's genes, and make them suitable for large-scale urban agriculture for the first time.

With CRISPR, researchers can precisely target and cut any kind of genetic material. Don't want your mushrooms to turn brown after a few days? Remove the gene that causes thatand problem solved.

There's a lot of excitement about the introduction of gene-edited products into the Canadian food system over the next few years, but a lot of trepidation as well.

The food industry's last foray into genetic engineering genetically modified organisms (GMOs) in the 1990s was a financial success. But the practice is an ongoing public relations nightmare, as many Canadians remain wary of products critics have labelled "Frankenfoods."

Currently, the only gene-edited product commercially available is a soybean oil being used by a restaurant chain in the American Midwest for cooking and salad dressings. It has a longer shelf life than other cooking oils and produces less saturated fat and no trans fat.

Ian Affleck, vice-president of plant biotechnology at CropLife Canada, a trade association that represents Canadian manufacturers of pesticides and plant-breeding products, estimates the soybean oil might be in Canada in a year or two, followed by some altered fruits and vegetables.

Even then, he said, supplies will likely be limited while farmers and food companies determine if consumers will embrace genetically edited food.

All the major health organizations in the world, including Health Canada, have concluded that eating GMO foods does not pose eithershort or long-term health risks.

According to the World Health Organization, GMO goods currently approved for the market "have passed safety assessments and are not likely to present risks for human health."

But Canadians remain stubbornly unconvinced even though about 90 per cent of the corn, soybeansand canola grown in Canada is genetically modified, as is almost all of the processed food we consume.

A 2018 pollby market research company Statista found only 37 per cent of people surveyed strongly or somewhat strongly agreed that GMOs were safe to eat, while 34 per cent strongly or somewhat strongly disagreed.

Industry representatives now say they spent too much time marketing their GMOproducts to farmersand not enough time communicating the benefitsto consumers.

"We spoke to two per cent of the population, who are those who farm," said Affleck. "And those who opposed the technology spoke to the other 98 per cent of the population."

"We thought it was just another transition in plant breeding," recalled Stuart Smyth, who holds the University of Saskatchewan's industry-funded research chair in agri-food innovation. "Nobody expected the environmental groups to develop into a political opposition."

With gene-edited foods, Smyth believes the industry needs to focus on public education to counteract what he calls the "propaganda" that will be coming from the other side.

Gene-edited foods will differ from GMOs in one important respect.

When foods are genetically modified, foreign genes are often added to an existing genome. If you want a vegetable to grow better in cold weather, you could add a gene from a fish that lives in icy water.That's what earned GMO products the "Frankenfoods" moniker.

With gene-editing tools like CRISPR, genes can be cut out, or "turned off," but nothing new is added to the genome.

Lucy Sharratt, co-ordinator of the Canadian Biotechnology Action Network, isn't convinced there's a significant difference.

"The new techniques of gene editing are clearly techniques of genetic engineering," she said. "They are all invasive methods of changing a genome directly at the molecular level.

"While we can produce organisms with new traits, that doesn't mean we know exactly all of what we've done to that organism. There can be many unintended effects," Sharratt further argued.

Unlike GMOs, which require extensive regulatory approval before going to market, gene-edited foods will likely appear without undergoing a risk assessment by Canadian regulators.

Health Canada doesn't require safety testing for new products if it determines those products aren't introducing "novel traits" into the food system. Since it considers gene editing to be an extension of traditional plant breeding, no stamp of approval will be necessary.

That concerns Jennifer Kuzma, co-director of the Genetic Engineering and Society Center at North Carolina State University, whothinks gene-edited products should be tracked and monitored "for those low-level health effects that some products might be contributing to."

Sharratt is also skeptical that gene editing will produce the benefits its supporters claim, pointing to "a biotech industry that has oversold technology and made all kinds of broad promises for the use of genetic engineering that didn't come to pass." Things like reduced pesticide use and greater drought resistance, for example.

Kuzma agrees that GMO researchers have sometimes been guilty of "perhaps overstating the promise of the technology and understating potential risk."But she believes those involved in developing gene-editing techniques want to avoid repeating the mistakes of the past.

"They have a really sincere desire to be more open and transparent in the ways that they communicate and in the sharing of information," she said. "They do realize that the first generation of genetic engineering did not go so well from a public confidence perspective."

The GMO food industry has fiercely opposed one of the most obvious methods to boost public confidence: mandatory labelling, even as a 2018 survey from Dalhousie University showed an overwhelming majority of Canadians support it.

Sixty-four countries require mandatory labelling for GMO products. Canada is not one of them.

There are no plans to require mandatory labelling of gene-edited foods, either.

Jonathan Latham, executive director of the Bioscience Resource Project, a New York-based non-profit organization that researches genetic engineering, thinks that's a mistake.

"If you want people to make informed decisions and you want them to make that in a democratic fashion, then the more information you give them, the better," he said. "And so to deny people information about the content of their food is to violate a very basic democratic right."

Lathamalso believes that not labelling genetically engineered productsincreases consumer skepticism.

"[Consumers] don't really understand why, if a company wants to produce a product and advertise it and tell everybody how good it is, why they shouldn't also want to label it," he said.

Sharratt would like to see Canada adopt the approach taken by the European Court of Justice, which ruled in 2018 that gene-edited foods must undergo the same testing as GMOs before being allowed on grocery store shelves.

Lippman doesn't believe that will happen. In fact, he thinks the potential of gene-edited foods is so great that the public will demand even greater access to suchproducts.

"People will start to be educated and see that there's nothing harmful about it. It's completely fine. And then the only issue sticking out there will be whether we're over-promising.That'll be it."

Click 'listen' above to hear Ira Basen's documentary, The Splice of Life.

Read the original here:
Gene editing could revolutionize the food industry, but it'll have to fight the PR war GMO foods lost - CBC.ca

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. Well use ROE to examine Universal Vision Biotechnology Co., Ltd. (GTSM:3218), by way of a worked example.

Over the last twelve months Universal Vision Biotechnology has recorded a ROE of 11%. That means that for every NT$1 worth of shareholders equity, it generated NT$0.11 in profit.

Check out our latest analysis for Universal Vision Biotechnology

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

Or for Universal Vision Biotechnology:

11% = NT$183m NT$1.6b (Based on the trailing twelve months to September 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders equity is a little more complicated. It is the capital paid in by shareholders, plus any retained earnings. Shareholders equity can be calculated by subtracting the total liabilities of the company from the total assets of the company.

ROE looks at the amount a company earns relative to the money it has kept within the business. The return is the yearly profit. That means that the higher the ROE, the more profitable the company is. So, all else equal, investors should like a high ROE. That means it can be interesting to compare the ROE of different companies.

One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. Pleasingly, Universal Vision Biotechnology has a superior ROE than the average (8.8%) company in the Healthcare industry.

That is a good sign. We think a high ROE, alone, is usually enough to justify further research into a company. For example you might check if insiders are buying shares.

Companies usually need to invest money to grow their profits. That cash can come from issuing shares, retained earnings, or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.

While Universal Vision Biotechnology does have a tiny amount of debt, with debt to equity of just 0.051, we think the use of debt is very modest. The fact that it achieved a fairly good ROE with only modest debt suggests the business might be worth putting on your watchlist. Judicious use of debt to improve returns can certainly be a good thing, although it does elevate risk slightly and reduce future optionality.

Return on equity is useful for comparing the quality of different businesses. In my book the highest quality companies have high return on equity, despite low debt. If two companies have around the same level of debt to equity, and one has a higher ROE, Id generally prefer the one with higher ROE.

But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. Profit growth rates, versus the expectations reflected in the price of the stock, are a particularly important to consider. Check the past profit growth by Universal Vision Biotechnology by looking at this visualization of past earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

View post:
Should You Be Impressed By Universal Vision Biotechnology Co., Ltd.s (GTSM:3218) ROE? - Simply Wall St

The World Potato Congress (WPC) is pleased to be offering thefirst webinar in its 2020series featuring Dr. David Douches on January 24, 2020 at 09:00 AM Eastern Standard Time (USA and Canada).

Abstract:The Feed the Future Biotechnology Potato Partnership (BPP) is a five-year, multi-institution cooperative agreement between MSU, USAID, Simplot Company and other global institutions to develop and bring to market improved potato products to low-income farmers in South East Asian countries.

BPP offers biotech potato products with broad-spectrum resistance to late blight (Phytophthorainfestans), the most devastating potato disease in the world, and highly endemic throughout Bangladesh and Indonesia. BPP provides strategic human and institutional capacity building and support (research, development and outreach) to in-country partners in Bangladesh (BARI) and Indonesia (ICABIOGRAD) to support access to, technology transfer, and sustainable use of biotech potato technologies.

The project also monitors and evaluates environmental impact, gender balance contribution and socio-economic impact of these biotechnologies. BPP and partner institutions will steward biotech potato products for distribution to low-income farmers and eventual commercialization. All of these activities support and align with USAIDs goal of increasing food security and resilience.

Dr. David S. Douches, with over 36 years of experience inpotato breeding and genetics, has an active potato breeding program directedtoward the development of improved cultivars in Michigan for 30 years.

Thefocus of the program is to develop new cultivars for Michigans potato industryby integrating new genetic engineering techniques with conventional breedingefforts.Key traits targeted forimprovement include Colorado potato beetle resistance, disease resistance to scab, lateblight and PVY, as well as chip processing from long-term storage.

Dr. Douches is the principle scientist of the Michigan State Universitypotato breeding and genetics program and Director of the USAID-fundedFeed the Future Biotechnology Potato Project for Indonesia and Bangladesh.

The host for the WPC webinar series will be WPC Director, Dr. Nora Olsen (norao@uidaho.edu).

Webinar RegistrationInterested participants will be able to interact with the presenterof the webinar. When: January 24, 2020 at 09:00 AM Eastern Standard Time (USA and Canada)

Register in advance for this webinar:https://zoom.us/webinar/register/WN_Svl0vOiUQyKZqtjfYCzqpgFollowing your registration, you will receive a confirmation email containing information about how to join the webinar.

All webinars are recorded and can be viewed via the World Potato Congresswebsite at http://www.potatocongress.org.

In case you missed any of WPCs 2019webinars listed below, they can be viewed on our website at http://www.potatocongress.org :

1.World Potato Congress Inc. Premier Global Networking OrganizationPresenter: WPC President, Romain Cools, Belgium

2.Geographic Constraints in Potato Breeding: Role of Day Length, Temperature and Light Intensity in Selecting for AdaptationPresenter: Dr. Peter VanderZaag, Sunrise Potato Storage Ltd., Canada

3.Best Management Practices for Seed Potato Handling from Storage to PlantingPresenter: Dr. Gary Secor, Professor in the Department of Plant Pathology, North Dakota State University, USA

4.World Potato Output and TradePresenter: Cedric Porter, Editor, Brexit Food & Farming and co-editor of World Potato Markets, UK

5.Why You Should Plant Certified Seed PotatoesPresenter: Dr. Nina Zidack, Director of Seed Potato Certification, Montana State University, USA

6. Illustration of Regional Potato Promotion:Flanders (Belgium)Presenter:Kris Michiels, Marketing Adviser, VLAM, Belgium

WPC looks forward to interacting with you during this initiative. We welcome all your feedback via email:info@potatocongress.org.

Like Loading...

Categories: Across Regions, All latest News, Breeding, Events, News January 2020, North America, Pests and Diseases, Pressreleases, Production/Agronomy, Research, Studies/Reports, Varieties

Read the rest here:
Webinar: Feed the Future Biotechnology Potato Partnership: Durable late blight resistance to South East Asia - Potato News Today

Nasdaq recently announced the results of the annual re-ranking of the Nasdaq Biotechnology Index (NBI). The re-ranking was effective prior to market open on Monday, December 23, 2019. There are now 217 companies in the index, including 40 new additions. You can view the full list of securitieshere.

Along with this performance was a substantial increase in assets under management (AUM) for IBB the largest corresponding ETF that tracks the Nasdaq Biotechnology Index globally. In fact, the AUM as of December 31, 2019 was approximately $8B.

Since its inception, the NBI has shown impressive performance over the years. The market capitalization weighted index focuses specifically on the biopharmaceutical industry allowing Nasdaq-listed companies to gain exposure to passive investors.

Nasdaq continues to be the leader in biotechnology listings, including initial public offerings in the biotechnology and pharmaceutical arena such as Genmab, Bridge Bio and Gossamer Bio, Inc. In 2019, Nasdaq had a 100% BioPharma IPO win rate as we welcomed 55 BioPharma IPOs raising approximately $5.6 billion in IPO proceeds.

If you have any questions, including how to leverage inclusion in the index, please do not hesitate to contact me at Jordan.Saxe@nasdaq.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more:
40 Securities Added to Nasdaq Biotechnology Index - Nasdaq

Paris, France, January 9, 2020 Alderaan Biotechnology, a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer, announces today the successful completion of a Series A funding of 18.5M ($20.7M) from investors Advent France Biotechnology (AFB) and Medicxi. This follows a seed funding round of 1.5M ($1.7M) in 2017, led by AFB.Founded by Pr Armand Bensussan, head of the Skin Research Centre, Saint Louis Hospital, Paris, and Pr Daniel Olive, head of the Immunity and Cancer team at Institut Paoli Calmette, Marseille, Alderaan Biotechnology focusses on developing technologies to deplete regulatory T (Treg) cells in cancer and to boost Natural Killer (NK) cell cytotoxic activity in cancer, both emerging as new immunotherapy modalities.This funding round will support the finalization of preclinical development to reach Phase I clinical stage, with the companys Treg depleting CD25-specific antibodies, by 2022. In parallel, the financing will also help validate thein vivotherapeutic potential of the NK asset related to the activating NK cell receptor CD160-TM (Alderaans second program).Both Medicxi and AFB, represented by Michle Ollier and Matthieu Coutet respectively, will co-lead the new investment as board directors.I am very pleased to welcome Medicxi to the company; its capital investment signals an exciting stage for Alderaan, said Arnaud Foussat, CEO of Alderaan Biotechnology. Modulating regulatory T-cells in cancer has a great therapeutic potential in oncology it could be a game changer. Our NK asset is earlier stage, but there is already a strong and encouraging interest from the pharmaceutical industry in the field.We have been working alongside Alderaan since day one and we are thrilled to be part of this next stage of development, said Matthieu Coutet, managing partner at Advent France Biotechnology. Alderaans area of focus is drawing attention from big names in the industry and the company has a solid scientific team to support its rationale.Alderaan perfectly fits with our aim, which is to invest in start-ups that have already reached scientific maturation and proof-of-concept, said Michle Ollier, partner at Medicxi. The companys technologies are very attractive to the pharmaceutical industry and could become key additional therapeutic tools for patients and health professionals.Advisors to AlderaanLegal: Mac DermottFinancial: DeloitteAdvisors to MedixciLegal: Jones DayAbout Advent France BiotechnologyAdvent France Biotechnology is an AMF regulated firm created in 2016. The team, managed by Alain Huriez and Matthieu Coutet, includes professionals with extensive scientific, medical and operational experience, as well as a long-standing track record of entrepreneurial and investment successes across Europe. AFB invests in a range of sectors within the life sciences, specifically in drug discovery and new medical technologies.www.adventFB.comAbout MedicxiMedicxi is a European venture capital firm with the mission to create and invest in companies along the full drug development continuum. Medicxi was established by the former Index Ventures life sciences team, which has been active for over 20 years, and invests in both early and late-stage assets with a product vision that can fulfil a clear unmet need.GSK, Johnson & Johnson Innovation JJDC, Inc.,Novartis and Verily (an Alphabet company) have invested in Medicxi funds.www.medicxi.comAbout Alderaan BiotechnologyAlderaan Biotechnology is a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer with technologies aiming at Treg depletion and NK cell modulation. Founded in 2017 and headquartered in Paris, Alderaan works with world-class teams in the field of immunomodulation and NK cell receptors. The company raised 1.5M ($1.7M) in 2017 from co-founder Advent France Biotechnology (AFB) and 18.5M ($20.7M) in 2019 from AFB and Medicxi.www.linkedin.com/company/alderaan-biotechnology/about/

The rest is here:
Alderaan Biotechnology raises 18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi - BioSpace

In silico clinical trials pioneer Novadiscovery SA has raised 5m in a series A financing led by Swiss Debiopharm Innovation Fund.

French in silico clinical trial specialist Novadiscovery said it will use the 5m tranche of a 7m Series A funding round with Debiopharm Innovation Fund SA to scale its in silico clinical trial simulation platform Jink from a consulting to software as a service (SaaS) model, which is compliant with FDA priorities and requirements. Novadiscovery pioneers the use of in silicoclinical trials prior to human drug testing to predict drug efficacy and optimize clinical trail design. Several hundred disease and disease subtype-specific parameters are combined in the company's in silico models that mimic the physiology and co-morbidities of virtual patients.

Knowledge-based in silico modelling of clinical trials holds the potential to predict outcomes and optimise the design of clinical trials with the aim to reduce research & development (R&D) costs and time-to-market of novel drugs. Most recently, Novadiscovery accurately modelled the Phase I outcomes of the FXR agonist EYP001 in healthy and subjects infected with the hepatitis B virus (HBX) in a Phase I study. Furthermore, Jink was used to predict Phase II outcomes of a combination of EYP001 with standard therapy.

The Computational Model integrates 300+ biological variables and 600+ parameters. With seven mechanistic submodels (including the effect of FXR agonist on HBV replication, HBV excretion, bile acid physiology and EYP001, ETV, and pegylated interferon drug models), the model has been used to predict quantitative efficacy of treatments on disease-related endpoints (eg. plasma HBV DNA and HBsAg concentrations) in a virtual population. All the submodels are ultimately combined into a multi-scale Computational Model simulating the dynamics of biological entities at the molecular, cellular and organ levels.

We have seen the significant positive impact our in silico trials platform can have on reducing R&D costs and compressing time-to-market for new drugs and in drug repositioning, stressed Franois-Henri Boissel, CEO and Co-Founder of Nova. This funding allows us to accelerate the development of our platform in a SaaS model that will make it available to a growing number of clients and project, notably in the US. We intend to complete the 7m Series A in 2020.

Reducing R&D costs and time-to-market has become a key strategic objective for healthcare companies and payors. The in silico trial market is evaluated to grow to $2,88bn in annual revenue by 2022, when it will still represent only a small fraction of $165bn annual drug R&D spent.

Reducing number of real patients involved in clinical trials is also a main issue, for both the industry and the regulators. Because they are not so many considering the number of drugs to be evaluated, and their participation in a clinical trial must be as ethical as possible. Novas unique hybrid approach to running in silico clinical trials presents several benefits, one of which being that it can operate in data-poor environments, which is the biggest hurdle more conventional artificial intelligence (AI)-based approaches are facing.

View original post here:
Novadiscovery takes off with 5 Series A financing - European Biotechnology

Published: 16:50 Updated: 17:04 Monday 06 January 2020

A renowned scientist and former Tomorrows World presenter has been announced as one of the keynote speakers at the Industrial Biotechnology Innovation Centre (IBioIC) annual conference next month.

Vivienne Parry will address the event, which is now in its sixth year and expected to attract more than 450 delegates including IB business leaders, policy-makers, investors and innovators and technical experts from around the world. They will congregate in Glasgow on 5 and 6 February, and will see innovative companies exhibiting their smart solutions to a global audience.

Parry, a scientist by training, is the head of engagement at Genomics England and a UK Research and Innovation board member and has extensive writing and broadcasting experience that has inspired a generation of scientists.

She said industrial biotechnology (IB) start-ups need to get out and tell people what they are doing, quickly showing the solution to a problem scientists can sometimes struggle to communicate to policy-makers and the public the significance of what they are doing to save the planet.

READ MORE: Comment: Ever heard of industrial biotechnology? Our future may depend on itREAD MORE: Plans to boost Scotlands bio-revolution secure seed fundingKeep it simple and show the real value in your product and the positive impact it can make to everyday life and the environment. When I listen to someone presenting their concepts, I want them to excite me about the potential of their product in a way that is not hyped, but is really clear.

Mark Bustard, commercial director at IBioIC, said a change in mindset is needed if startups are to capitalise on their innovations. Companies like ScotBio, Cellucomp and Celtic Renewables are all fantastic examples of award-winning organisations who are driving science to generate and make products.

Link:
Former Tomorrows World presenter set to address biotechnology event - The Scotsman

Debut Biotechnology

SAN DIEGO (PRWEB) January 07, 2020

Debut Biotechnology, a UC-Irvine spinout that is advancing scalable cell-free biomanufacturing, today announced that it has closed a $2.6M seed round from leading venture capital firms and angel investors. The oversubscribed round was led by KdT Ventures, with participation from Better Ventures, FTW Ventures, and SpringTide Ventures.

We invested in Debut because the way we produce therapeutics and high value chemicals will dramatically change in the next 10 years as the pharma industry transitions from complex, multi-step batch manufacturing, to a far more cost-effective and efficient continuous manufacturing system, said Cain McClary, Founder and Managing Partner of KdT Ventures. Debut Bio will be at the forefront of this shift, which we believe represents one of the most promising opportunities in pharma.

Debut Bio helps the pharmaceutical and specialty chemical industries manufacture high-value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. Through the utilization of plug-and-play enzyme cartridges, the companys cell-free platform has the ability to transform low-value bio-renewable materials into high value therapeutics and specialty chemicals.

At our core, we are rethinking industrial biomanufacturing and aiming to produce high value molecules in better ways. Natures enzymes have the ability to create complex natural products, so why reinvent the wheel with chemical synthesis? said Dr. Joshua Britton, CEO and Founder of Debut Biotechnology. Enzyme pathways and evolved proteins hold the key.

Debut Bios enzyme cartridges are sequentially arranged in a manner which mimics pathways found in plants and other organisms. Each cartridge is finely-tuned to provide the ideal temperature, pH, concentration, solvent, and reaction time for each individual step to maximize enzymatic productivity and product titer levels. The platform requires far fewer steps than traditional pharma manufacturing and avoids the use of environmentally harmful chemistry. Importantly, it overcomes many challenges typically associated with relying on cells for biomanufacturing.

Bacteria and yeast have been the workhorses of industrial biomanufacturing for years. Unfortunately, these biofactories have their drawbacks; reaction times can be slow, the product and starting material have difficulty passing through the cell wall, and each cell must be reprogrammed to produce a new molecule, said Dr. Britton. Debut Bio envisions an alternative route.

In Debut Bios system, reactants are passed from one enzyme reactor to another to build in-vitro or cell-free biosynthetic pathways. The companys platform uses a sustainable approach by leveraging advanced enzymes outside of the cell to maximize performance and avoid issues with cell-based systems. The platform technology operates under a continuous manufacturing regime that will provide scale, consistency, and ultimately the ability to produce a biomolecule with the click of a button.

Debut Bio has currently partnered with two large manufacturers to integrate its platform into their existing pipelines. The seed funding will be used to support these integrations, expand business development, double the science team, and create a pilot production system.

Were humbled to have received both support and validation from world class, science-focused investors, said Brady Beauchamp, COO and Co-Founder of Debut Biotechnology. We plan to build on this validation in the coming months with our initial customers in the pharmaceutical manufacturing industry.

This funding comes following an announcement last year that the company spun out of UC Irvine with the exclusive license of two inventions developed by Dr. Joshua Britton and Professor Greg Weiss.

To learn more, please visit: https://debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology is commercializing cell-free biomanufacturing solutions by creating advanced enzyme-based manufacturing processes for high-value molecules. Our platform combines immobilized enzymes with highly controlled and automated continuous manufacturing systems for the pharmaceutical and specialty chemical industries.

Debut Biotechnology was founded by Joshua Britton, Greg Wess, and Brady Beauchamp and is based in sunny San Diego. To learn more, please visit: https://debutbiotech.com/.

Share article on social media or email:

Read more:
Debut Biotechnology Closes $2.6M Seed Round to Bring Continuous Biomanufacturing of High-Value Molecules to Pharma - PR Web